News
- 2024/05/08
- Received ‘AA’ for the first time in MSCI ESG Ratings
- 2023/12/15
- NIPPON KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDx TM IN JAPAN
- 2023/10/19
- Updated information of sustainability
- 2023/10/18
- Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication
- 2023/09/25
-
Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody.
- 2022/11/16
-
Launch in Japan of Bevacizumab BS for I.V. Infusion 100mg・400mg “CTNK” ,an anti-VEGF humanized monoclonal antibody
- 2021/06/30
-
New Late-Breaking Data at The American Diabetes Association Show GlycoMark May Be an Effective Test for COVID-19 Severity
